Overview

Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS

Status:
Enrolling by invitation

Trial end date:
2022-02-28

Target enrollment:

Participant gender:

Summary

ZYN002 is a pharmaceutically manufactured Cannabidiol (CBD) that is developed as a clear gel that can be applied to the skin (called transdermal delivery). The gel will be applied to clean, dry, intact skin of the shoulders and/or upper arms. Only participants from the ZYN2-CL-016 study who meet the inclusion criteria and none of the exclusion criteria for study ZYN2-CL-017 are eligible. Parents/caregivers will apply the study gel twice daily for the 52-week treatment period.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Zynerba Pharmaceuticals, Inc.

Treatments:

Cannabidiol